The study achieved the primary endpoint of non-inferiority, with a rate of all-cause mortality (ACM) at Day 42 for olorofim of 23.8% and for AmBisome&r...
Rapidly Advancing Five IRD Programs with Four Clinical Data Readouts Expected in 2027 RDH12, MERTK and RHO Programs Expected to Enter Clinical Testing o...
TALVEY® plus daratumumab with or without pomalidomide showed progression-free survival of up to 81.3% and overall survival of up to ...
Results from the Phase 2 EPCORE® DLBCL-3 trial show fixed-duration epcoritamab monotherapy demonstrated early responses in elderly patients with ne...
Acousia Therapeutics GmbH, a clinical-stage biotechnology company pioneering treatments for acute and chronic inner ear hearing loss, announced positive ...
New registry will generate robust real-world evidence on disease burden, treatment patterns and long-term effectiveness of newly approved and emerging th...
The promise of precision oncology depends not only on scientific innovation but also on successful implementation in routine clinical practice. Drawing on ...
As oncology practices face increasing patient demand and looming workforce shortages, advanced practice providers (APPs) are becoming an essential part of ...
As oncology care becomes increasingly personalized and technology-enabled, digital tools are playing a growing role in improving patient outcomes beyond th...
Twelve-month findings showed improvement in Composite Unified Huntington's Disease Rating Scale (cUHDRS) scores from baseline of +0.38, compared to an ex...
First investigational PD-(L)1xVEGF bispecific immunomodulator to present global data showing encouraging efficacy in combination with ch...
Orion Pharma announces first results from Phase 1/2 TEADES trial with TEAD inhibitor ODM-212 in patients with advanced solid tumours Data presented at...
UCB and Biogen Inc.announced that The Lancet, a world-leading medical journal, has published the full results from the Phase 3 PHOENYCS G...
Delivers strong Q2 results and raises FY26 revenue growth, margin expansion, and non-GAAP EPS(4) guidance on continued operational momentum Second-qua...
© 2026 Biopharma Boardroom. All Rights Reserved.
